10-QPeriod: Q2 FY2020

HCA Healthcare, Inc. Quarterly Report for Q2 Ended Jun 30, 2020

Filed July 30, 2020For Securities:HCA

Summary

HCA Healthcare, Inc. (HCA) reported its second-quarter 2020 results, a period significantly impacted by the COVID-19 pandemic. While consolidated revenues declined 12.2% year-over-year to $11.068 billion, net income attributable to HCA Healthcare, Inc. increased by 37.9% to $1.079 billion, or $3.16 per diluted share. This increase was largely driven by substantial government stimulus income received under the CARES Act, totaling $822 million ($590 million net of tax) in the quarter. Despite the revenue decline stemming from a significant drop in patient volumes, particularly elective procedures, the company's ability to increase revenue per equivalent admission by 9.7% partially offset the volume decrease. Operationally, HCA experienced a 20.0% decline in equivalent admissions, alongside a 26.5% decrease in surgeries and a 32.7% drop in emergency department visits. The company took proactive steps to enhance financial flexibility, including suspending share repurchases and dividends, and securing additional credit facilities. Cash flow from operations saw a substantial increase due to CARES Act funding and positive working capital changes. The company continues to monitor the evolving impact of the pandemic and has adjusted capital expenditures accordingly, while emphasizing its strong liquidity position to meet near-term obligations.

Financial Highlights

48 data points
Beta

Revenue

$11.07B

Net Income

$1.08B

9.7% Net Margin

EPS (Diluted)

$3.16

Total Assets

$48.71B

Cash & Equivalents

$4.64B

Free Cash Flow

$7.98B

Financial Statements
Beta
Revenue$11.07B
Operating Expenses$9.51B
Interest Expense$388.00M
Net Income$1.08B
EPS (Basic)$3.20
EPS (Diluted)$3.16
Shares Outstanding (Basic)337.76M
Shares Outstanding (Diluted)341.60M

Key Highlights

  • 1Second quarter 2020 revenues decreased 12.2% to $11.068 billion compared to $12.602 billion in Q2 2019, primarily due to a 20.0% decline in equivalent admissions.
  • 2Net income attributable to HCA Healthcare, Inc. increased significantly by 37.9% to $1.079 billion ($3.16 per diluted share) in Q2 2020, up from $783 million ($2.25 per diluted share) in Q2 2019.
  • 3Government stimulus income of $822 million ($590 million net of tax) related to the CARES Act was a significant contributor to Q2 2020 net income.
  • 4Despite a 20.0% decline in equivalent admissions, revenue per equivalent admission increased by 9.7% in Q2 2020 compared to Q2 2019.
  • 5Patient volumes were severely impacted by COVID-19, with equivalent admissions down 20.0%, surgeries down 26.5%, and emergency department visits down 32.7% in Q2 2020.
  • 6Cash flow from operating activities significantly increased to $8.723 billion in Q2 2020 from $1.997 billion in Q2 2019, largely due to CARES Act payments and working capital improvements.
  • 7HCA suspended its share repurchase program and quarterly dividend program in response to the COVID-19 pandemic and reduced planned capital expenditures.

Frequently Asked Questions

The COVID-19 pandemic significantly impacted HCA Healthcare's operations, leading to a 12.2% decrease in consolidated revenues to $11.068 billion. This was primarily driven by a substantial decline in patient volumes, particularly for elective procedures, resulting in a 20.0% drop in equivalent admissions. However, the company received approximately $822 million in government stimulus income under the CARES Act, which significantly boosted net income to $1.079 billion, a 37.9% increase year-over-year.

The CARES Act funding was crucial for HCA Healthcare's second-quarter performance. The company received $822 million in government stimulus income (net of tax, $590 million), which directly contributed to its reported net income. This funding helped offset the revenue losses incurred due to reduced patient volumes caused by the pandemic.

In response to the pandemic's uncertainties, HCA Healthcare took several measures to enhance its financial flexibility. These included suspending its share repurchase program and quarterly dividend program, reducing planned capital expenditures, and securing a new $2 billion term loan facility. The company also received significant accelerated Medicare payments and Provider Relief Fund distributions under the CARES Act, which substantially boosted its cash flows.

Operationally, HCA experienced significant declines in patient volumes. Equivalent admissions dropped by 20.0%, surgeries decreased by 26.5%, and emergency department visits fell by 32.7% compared to the prior year. Despite these volume declines, the company was able to increase revenue per equivalent admission by 9.7%, indicating a potential shift towards higher-acuity cases or improved pricing strategies.